Ontology highlight
ABSTRACT: Purpose
c-MET and its ligand hepatocyte growth factor are often dysregulated in human cancers. Dynamic changes in c-MET expression occur and might predict drug efficacy or emergence of resistance. Noninvasive visualization of c-MET dynamics could therefore potentially guide c-MET-directed therapies. We investigated the feasibility of 89Zr-labelled one-armed c-MET antibody onartuzumab PET for detecting relevant changes in c-MET levels induced by c-MET-mediated epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib resistance or heat shock protein-90 (HSP90) inhibitor NVP-AUY-922 treatment in human non-small-cell lung cancer (NSCLC) xenografts.Methods
In vitro membrane c-MET levels were determined by flow cytometry. HCC827ErlRes, an erlotinib-r
SUBMITTER: Pool M
PROVIDER: S-EPMC5486818 | biostudies-literature | 2017 Aug
REPOSITORIES: biostudies-literature